Teacher Retirement System of Texas grew its holdings in shares of Illumina, Inc. (NASDAQ:ILMN - Free Report) by 15.0% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 669,730 shares of the life sciences company's stock after buying an additional 87,252 shares during the quarter. Teacher Retirement System of Texas owned 0.42% of Illumina worth $53,136,000 at the end of the most recent reporting period.
Other hedge funds have also recently made changes to their positions in the company. Capital World Investors boosted its stake in Illumina by 408.6% during the 4th quarter. Capital World Investors now owns 18,025,301 shares of the life sciences company's stock valued at $2,408,721,000 after purchasing an additional 14,481,232 shares during the last quarter. Brown Advisory Inc. boosted its position in shares of Illumina by 54,220.9% during the fourth quarter. Brown Advisory Inc. now owns 1,912,639 shares of the life sciences company's stock valued at $255,586,000 after buying an additional 1,909,118 shares during the last quarter. Norges Bank purchased a new position in shares of Illumina during the fourth quarter valued at approximately $228,714,000. Bessemer Group Inc. boosted its position in shares of Illumina by 32,837.5% during the fourth quarter. Bessemer Group Inc. now owns 1,348,131 shares of the life sciences company's stock valued at $180,152,000 after buying an additional 1,344,038 shares during the last quarter. Finally, Assenagon Asset Management S.A. boosted its holdings in Illumina by 2,057.5% during the 1st quarter. Assenagon Asset Management S.A. now owns 922,281 shares of the life sciences company's stock worth $73,174,000 after acquiring an additional 879,533 shares during the last quarter. 89.42% of the stock is currently owned by institutional investors and hedge funds.
Insider Activity
In other Illumina news, CFO Ankur Dhingra acquired 6,100 shares of the stock in a transaction that occurred on Monday, May 12th. The shares were bought at an average price of $81.21 per share, for a total transaction of $495,381.00. Following the completion of the transaction, the chief financial officer owned 24,906 shares of the company's stock, valued at approximately $2,022,616.26. This represents a 32.44% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 2.60% of the company's stock.
Analyst Ratings Changes
ILMN has been the topic of a number of analyst reports. JPMorgan Chase & Co. cut their price objective on shares of Illumina from $120.00 to $85.00 and set a "neutral" rating on the stock in a report on Friday, May 9th. Citigroup cut their price target on shares of Illumina from $90.00 to $85.00 and set a "neutral" rating on the stock in a report on Monday, April 7th. Morgan Stanley cut their target price on Illumina from $136.00 to $100.00 and set an "equal weight" rating on the stock in a research note on Monday, May 12th. Royal Bank Of Canada cut their target price on Illumina from $128.00 to $112.00 and set an "outperform" rating on the stock in a research note on Tuesday, April 8th. Finally, Canaccord Genuity Group boosted their price objective on Illumina from $87.00 to $99.00 and gave the stock a "hold" rating in a research report on Wednesday, June 11th. One analyst has rated the stock with a sell rating, nine have given a hold rating, nine have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $127.39.
View Our Latest Report on ILMN
Illumina Price Performance
Shares of Illumina stock traded up $0.10 on Friday, reaching $100.44. The stock had a trading volume of 1,423,748 shares, compared to its average volume of 2,144,110. Illumina, Inc. has a 1 year low of $68.70 and a 1 year high of $156.66. The company has a market cap of $15.90 billion, a P/E ratio of -16.55, a price-to-earnings-growth ratio of 1.98 and a beta of 1.36. The company has a current ratio of 1.86, a quick ratio of 1.48 and a debt-to-equity ratio of 0.63. The business's 50 day moving average is $85.04 and its two-hundred day moving average is $97.73.
Illumina (NASDAQ:ILMN - Get Free Report) last posted its earnings results on Thursday, May 8th. The life sciences company reported $0.97 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.96 by $0.01. Illumina had a negative net margin of 22.25% and a positive return on equity of 25.54%. The business had revenue of $1.04 billion for the quarter, compared to analysts' expectations of $1.03 billion. During the same period in the prior year, the company posted $0.98 EPS. The business's revenue for the quarter was down 1.4% compared to the same quarter last year. As a group, research analysts anticipate that Illumina, Inc. will post 4.51 EPS for the current year.
Illumina Profile
(
Free Report)
Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.
Read More

Before you consider Illumina, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Illumina wasn't on the list.
While Illumina currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.